NCT Number: NCT07461662
Endobronchial ultrasound (EBUS) bronchoscopy is commonly used to sample lymph nodes in patients with suspected or known lung cancer to determine the stage of the disease. Accurate staging is essential as it directly impacts treatment decisions and prognosis. During EBUS procedures, needles are often reused across multiple lymph node stations and are typically flushed with saline between samples. This raises the concern that residual tumor cells may contaminate the samples and could potentially incorrectly upstage disease.
This prospective study will evaluate the current technique used during EBUS procedures to determine if more intensive cleaning leads to reduced cellular contamination without affecting diagnostics. Patients undergoing an EBUS procedure for diagnosis with a large mass and a high probability of malignancy will be selected for the study. Rapid On-Site Examination (ROSE) will be used at the bedside to determine the presence of abnormal cells. Following the final pass, before moving to the next station, the needle will be flushed with saline as normal and then flushed again into another container to evaluate the presence of residual cells. The outcome may help EBUS needle handling practices and improve lung cancer staging accuracy.
No additional invasive procedures are performed as part of this study; all analyses utilize material obtained during routine EBUS needle flushing, with no added needle sticks or alteration of clinical care.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Jackson, Mississippi, 39216, United States
Agha Baqir, MD
SUB_INVESTIGATOR
George Abraham, MD
SUB_INVESTIGATOR
Michal Senitko, MD
SUB_INVESTIGATOR
Mick Kelly
SUB_INVESTIGATOR
Ricardo Ungo, MD
CONTACT
Ricardo Ungo, MD
SUB_INVESTIGATOR
Swathi Yarlagadda, MD
SUB_INVESTIGATOR
Syed Abbas, MD
SUB_INVESTIGATOR
Varsha Manucha, MD
SUB_INVESTIGATOR
Walter Rose, MD
SUB_INVESTIGATOR
Yanglin Guo, MD
CONTACT
EBUS guided transbronchial needle aspiration (TBNA) is a cornerstone in lung cancer staging. Accurate nodal staging under the TNM 9th edition guidelines is essential. Prior work has demonstrated that EBUS needle contamination can occur. A prospective multicenter study published in Archivos de Bronconeumologia demonstrates residual malignant cells despite repeated saline flushes with increasing flush volumes. A prospective observational study by Berim et al. showed malignant and non-malignant cellular debris can persist after multiple cleaning steps. Repeated flushing reduced but did not eliminate the contaminants, suggesting the current practice of flushing with saline may be insufficient to prevent contamination. The above studies demonstrate that contamination does exist in EBUS needle aspiration though there is no universal consensus on how to address contamination risk. The proposed project would identify cytologic contamination present in our current practices, without any additional risk from a procedural standpoint to the patient. This project would also examine the presence of malignant cells despite additional flushing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Additional flushing of the needle into a separate vial
Time frame: From enrollment to the date of the pathological review report of the specimen taken during diagnostic EBUS sampling for a period of up to 32 weeks post enrollment and randomization in trial for each patient enrolled.
To determine the presence of cytologic contamination following standard practice cleaning techniques
Time frame: From enrollment to the date of the pathological review report of the specimen taken during diagnostic EBUS sampling for a period of up to 32 weeks post enrollment and randomization in trial for each patient enrolled.
To evaluate the incidence of pathological upstaging based on our primary outcome findings
Time frame: From enrollment to the date of the pathological review report of the specimen taken during diagnostic EBUS sampling for a period of up to 32 weeks post enrollment and randomization in trial for each patient enrolled.
To establish whether enhanced flushing protocols are required to mitigate the risk of contamination as evidenced by a change in incidences of cytologic contamination as reported by pathologic assessment of specimens taken after enhanced cleaning techniques.
Contact information is provided by the study sponsor or research team.
Ricardo Ungo, MD
CONTACT
Yanglin Guo, MD
CONTACT
University of Mississippi Medical Center
Other
Acronym: EBUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07583316
Adenocarcinoma, Carcinoma
Beijing, Beijing Municipality, China
View Trial DetailsNCT07303881
Hematologic Diseases, Hematologic Disorder
Guangzhou, Guangdong, China
View Trial DetailsNCT07260058
Advanced Solid Tumors, Breast Cancer (Locally Advanced or Metastatic)
View Trial DetailsNCT07457541
Breast Cancer (Locally Advanced or Metastatic), Breast Diseases
Tomsk, Tomsk Oblast, Russia
View Trial Details